Novartis Returns to Growth on Sales Momentum From Key Drugs
Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling products offset declines for medicines that lost patent protection.
Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling products offset declines for medicines that lost patent protection.